Skip to main content

Table 1 Epidemiologic parameters and annual transition probabilities used in the model

From: Introduction of birth dose of hepatitis B virus vaccine to the immunization program in Ethiopia: an economic evaluation

Parameter Base assumptions Range for sensitivity analysis Source
Prevalence of HBsAg among pregnant women 0.047 0.025–0.1 [3]
Prevalence of HBeAg among HBsAg positive mothers 0.116 0.05–0.25 [4]
Risk of perinatal transmission (HBeAg +) 0.279 0.1–0.6 [4]
Risk of perinatal transmission (HBeAg−) 0.08 0.02–0.29 [4]
Acute symptomatic cases (for children of HBeAg + mothers) 0.01 [4]
Acute symptomatic cases (for children of HBeAg − mothers) 0.05 [23]
Fulminant infections among symptomatic cases 0.001 [15]
Risk of infant death from fulminant infection 0.7 [15]
Risk of infant chronic infection among survivors of fulminant infection 0.33 [15]
Risk of chronic HBV infection after perinatal infection 0.9 [4]
Chronic HBV infected individuals requiring antiviral treatment (CAH) 0.25 [20]
Inactive carriers among individuals with chronic HBV infection 0.75 [20]
Annual transition probabilities and disease related mortality
 Inactive carrier to
  CAH 0.03 [23]
  Compensated cirrhosis 0.007 [24]
  HCC 0.0006 [24]
 CAH toa    [24]
  Inactive carrier 0.55 0.3–0.7 [24]
  Compensated cirrhosis 0.0024 0.0012–0.0036 [24]
  HCC 0.003 0.002–0.007 [24]
 Compensated cirrhosis to
  Decompensated cirrhosis 0.035 [23]
  HCC 0.033 [23]
  Regression 0.24 [24]
 Decompensated cirrhosis to    
  Disease specific death 0.28 [23]
  HCC 0.15 [23]
 HCC to
  Disease specific death 0.29 [23]
Vaccine effectiveness 0.72 0.6–0.8 [27]
Vaccine utilization 0.5 0.1–0.66b [14]
  1. aIn our model, patients with chronic active hepatitis (CAH) are eligible for antiviral treatment therefore we used transition probabilities of treated patients
  2. bThe highest vaccine utilization rate was based on administrative report for facility delivery in Ethiopia